Drei-Jahres-Follow-up-Daten aus Phase-1-Studie mit individualisiertem mRNA-Immuntherapie-Kandidaten zeigen eine anhaltende Immunantwort und ein verringertes Rückfallrisiko bei einigen Patienten mit reseziertem Bauchspeicheldrüsenkrebs
April 07, 2024 14:00 ET | BioNTech SE
Drei-Jahres-Follow-up-Daten aus einer nichtkommerziellen Phase-1-Studie mit dem individualisierten mRNA-basierten Krebsimpfstoff-Kandidaten Autogene Cevumeran (BNT122, RO7198457) bei Patientinnen und...
Three-year Phase 1 F
Three-year Phase 1 Follow-Up Data for mRNA-based Individualized Immunotherapy Candidate Show Persistence of Immune Response and Delayed Tumor Recurrence in Some Patients with Resected Pancreatic Cancer
April 07, 2024 14:00 ET | BioNTech SE
Three-year follow-up data of an investigator-initiated Phase 1 trial of the individualized mRNA cancer vaccine candidate autogene cevumeran (BNT122, RO7198457) continue to show polyspecific T cell...
METC extended through March 31, 2025 The Government of Canada announced an extension to the Mineral Exploration tax Credit (METC) through March 31, 2025.
Immuneering-logo (1).png
Immuneering Doses First Patient in Phase 2a Clinical Trial of IMM-1-104 in RAS-mutant Solid Tumors
March 11, 2024 08:00 ET | Immuneering Corporation
- First patient dosed with IMM-1-104 in combination with modified gemcitabine plus nab-paclitaxel for first-line treatment of pancreatic ductal adenocarcinoma (PDAC) - - Phase 2a portion of Phase...
SLAM CEO Talking About Mine Road Acquisition at PDAC
March 04, 2024 14:51 ET | SLAM Exploration Ltd.
MIRAMICHI, New Brunswick, March 04, 2024 (GLOBE NEWSWIRE) -- SLAM Exploration Ltd. (TSXV-SXL) (“SLAM” or the “Company”) announces that CEO Mike Taylor is doing a presentation at The Atlantic Edge...
Halleck Creek Drill Rig
American Rare Earths to present at two leading industry conferences in March PDAC and International Battery Seminar
February 27, 2024 09:03 ET | American Rare Earths
DENVER, Feb. 27, 2024 (GLOBE NEWSWIRE) -- American Rare Earths (ASX: ARR | ADRs - OTCQX: AMRRY | Common Shares - OTCQB: ARRNF) (“ARR” or the “Company”) executives will participate in two upcoming...
EnGeneIC granted FDA “Fast-Track” Designation for Novel Armed Nanocell Drug Conjugate (ANDC) Pancreatic Cancer Therapeutic
December 07, 2023 19:51 ET | EnGeneIC
EneneIC has been granted Fast Track designation for use of its novel Armed Nanocell Drug Conjugate (ANDC) in PDAC patients.
EnGeneIC’s breakthrough Armed Nanocell Drug Conjugate (ANDC) treatment shows promising results in Pancreatic cancer patients who have run out of treatment options
November 26, 2023 23:37 ET | EnGeneIC
SYDNEY and NEW YORK, Nov. 26, 2023 (GLOBE NEWSWIRE) -- EnGeneIC, a pioneer in personalised cancer therapeutics, announces the publication of its clinical trial results in peer reviewed prestigious...
PDAC logo (bilingual; with text)).jpg
PDAC announces 2024 Award Recipients
November 09, 2023 10:00 ET | Prospectors & Developers Association of Canada (PDAC)
2024 PDAC Award Recipients: Osisko Mining - Wabun Tribal Council - O3 Mining - Lundin Group - Victoria Gold Corp.
Vaccinex logo
Vaccinex Reports Clinical Benefit in Interim Analyses from two Phase 2 Studies of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer’s Annual Meeting
October 31, 2023 09:00 ET | Vaccinex, Inc.
ROCHESTER, N.Y., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company, will be reporting novel findings for its lead product, pepinemab, in two...